💊Imagine... Improved Survival and Quality of Life for Pancreatic Cancer Patients💊

💡 Imagined Endstate: 

Pacific region will adopt and implement the new first-line treatment option for metastatic pancreatic cancer.

🔗Link: 

Ref Here

📚Source: 

Post, E. (2024, February 13). FDA Approves New First-line Treatment Option for Metastatic Pancreatic Cancer: What You Need to Know. Pancreatic Cancer Action Network.

💥 What’s the Big Deal: 

By  access and affordability to this treatment, the Pacific region will improve the outcomes and well-being of its pancreatic cancer patients, who often face poor prognoses and limited options.🌊Pancreatic cancer is often diagnosed late when it spreads to other organs and is difficult to treat.

 To treat metastatic pancreatic cancer, doctors typically use 2 chemotherapy drugs - gemcitabine and nab-paclitaxel. This treatment approach has shown a median overall survival rate of 9.2 months. The new treatment, NALIRIFOX, is a combination of three chemotherapy drugs, liposomal irinotecan, oxaliplatin, and fluorouracil/leucovorin, which has a median overall survival of 11.1 months.🎗️This is the first new first-line treatment for metastatic pancreatic cancer approved by the FDA in over ten years. The Pacific region has the opportunity and responsibility to make this treatment available and affordable for its pancreatic cancer patients, who deserve a better chance of living longer and better.

#PancreaticCancer, #Pacific, #NewTreatment, #Survival,#QualityofLife,#HealthAccess,#Innovation,#IMSPARK,